Lymphocyte infiltrates as a prognostic variable in female breast cancer - PubMed (original) (raw)
Lymphocyte infiltrates as a prognostic variable in female breast cancer
S Aaltomaa et al. Eur J Cancer. 1992.
Abstract
The predictive value of lymphocyte infiltrates (LI) was studied in 489 patients with breast cancer followed-up for over 10 years. LI were positively correlated to axillary lymph-node status, tumour diameter and histological and morphometric variables (P less than 0.001). In a multivariate analysis LI were independently related to axillary lymph-node status. LI predicted recurrence-free survival (RFS) in rapidly proliferating tumours (P = 0.0269). LI predicted RFS (P = 0.08) and breast cancer related survival (BS) (P = 0.0164) in rapidly proliferating, axillary lymph-node negative tumours. In a multivariate analysis LI independently predicted BS (P = 0.08) in rapidly proliferating tumours. LI independently predicted BS in rapidly (P = 0.025) and slowly (P = 0.09) proliferating, axillary lymph-node negative tumours. If the tumours were not categorised according to proliferation rate, LI and outcome were not significantly related. The results clearly confirm the presence of efficient immunological antitumour defence mechanisms in human breast cancer. Consequently tumour-host interactions are subject to further studies particularly in axillary lymph-node negative breast cancer.
Similar articles
- Mitotic indexes as prognostic predictors in female breast cancer.
Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, Syrjänen K. Aaltomaa S, et al. J Cancer Res Clin Oncol. 1992;118(1):75-81. doi: 10.1007/BF01192316. J Cancer Res Clin Oncol. 1992. PMID: 1729263 - The significance of nuclear morphometric variables as prognostic predictors in breast cancer.
Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, Syrjänen K. Aaltomaa S, et al. Anticancer Res. 1991 Jul-Aug;11(4):1663-9. Anticancer Res. 1991. PMID: 1746922 - Prognostic scores combining clinical, histological and morphometric variables in assessment of the disease outcome in female breast cancer.
Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, Syrjänen K. Aaltomaa S, et al. Int J Cancer. 1991 Dec 2;49(6):886-92. doi: 10.1002/ijc.2910490615. Int J Cancer. 1991. PMID: 1959993 - Histological assessment of the prognostic factors in female breast cancer.
Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Mari S, Alhava E, Syrjänen K. Aaltomaa S, et al. Oncology. 1992;49(1):1-8. doi: 10.1159/000227001. Oncology. 1992. PMID: 1542486 - Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.
Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, Kaul S, Bastert G. Diel IJ, et al. J Natl Cancer Inst. 1996 Nov 20;88(22):1652-8. doi: 10.1093/jnci/88.22.1652. J Natl Cancer Inst. 1996. PMID: 8931609
Cited by
- T lymphocyte-derived IFN-γ facilitates breast cancer cells to pass the blood-brain barrier: An in vitro study corroborating translational data.
Pedrosa RMSM, Kros JM, Schrijver B, Berrevoets C, Marques RB, van Eijck CCHJ, Debets R, Leenen PM, Dik WA, Mustafa DM. Pedrosa RMSM, et al. Heliyon. 2024 Aug 20;10(16):e36598. doi: 10.1016/j.heliyon.2024.e36598. eCollection 2024 Aug 30. Heliyon. 2024. PMID: 39262976 Free PMC article. - Targeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer.
Jama M, Tabana Y, Barakat KH. Jama M, et al. Eur J Med Res. 2024 Jul 2;29(1):353. doi: 10.1186/s40001-024-01901-9. Eur J Med Res. 2024. PMID: 38956700 Free PMC article. Review. - Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non-small cell lung cancer.
Cho U, Im S, Park HS. Cho U, et al. J Pathol Transl Med. 2024 Mar;58(2):49-58. doi: 10.4132/jptm.2024.01.31. Epub 2024 Feb 26. J Pathol Transl Med. 2024. PMID: 38389279 Free PMC article. Review. - Distinct profiles of proliferating CD8+/TCF1+ T cells and CD163+/PD-L1+ macrophages predict risk of relapse differently among treatment-naïve breast cancer subtypes.
Ntostoglou K, Theodorou SDP, Proctor T, Nikas IP, Awounvo S, Sepsa A, Georgoulias V, Ryu HS, Pateras IS, Kittas C. Ntostoglou K, et al. Cancer Immunol Immunother. 2024 Feb 13;73(3):46. doi: 10.1007/s00262-024-03630-8. Cancer Immunol Immunother. 2024. PMID: 38349444 Free PMC article. - Evaluation of immune density, PD-L1, and CXCR4 expressions in metaplastic breast carcinoma to predict potential immunotherapy benefit.
Bagbudar S, Karanlık H, Cabioglu N, Bayram A, Tükenmez M, Aydıner A, Yavuz E, Onder S. Bagbudar S, et al. Med Oncol. 2023 Dec 15;41(1):18. doi: 10.1007/s12032-023-02243-y. Med Oncol. 2023. PMID: 38102446
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical